Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

Area of Science:

• Oncology
• Molecular Biology
• Developmental Biology

Background:

• Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a significant propensity for metastasis.
• Understanding the molecular mechanisms driving PDA metastasis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate alterations in transcription and enhancer landscapes during pancreatic ductal adenocarcinoma (PDA) progression.
• To identify key molecular drivers of metastatic transition in PDA.

Main Methods:

• Utilized a mouse model of pancreatic ductal adenocarcinoma (PDA).
• Employed an organoid culture system to study transcriptional and enhancer landscape changes.
• Investigated the role of the pioneer factor FOXA1 in enhancer activation and PDA metastasis.

Main Results:

• Identified massive and recurrent alterations in enhancer activity accompanying the metastatic transition in PDA.
• Implicated FOXA1 as a driver of enhancer activation, leading to increased invasiveness and reduced anchorage dependence in vitro.
• Observed enhanced metastatic potential in vivo associated with FOXA1 activity.
• Demonstrated that FOXA1-dependent enhancer reprogramming activates an embryonic foregut endoderm transcriptional program.

Conclusions:

• Enhancer reprogramming and FOXA1 upregulation are key events in PDA metastasis.
• A retrograde developmental transition, driven by FOXA1, contributes to the metastatic capabilities of PDA.
• Targeting FOXA1 or the associated enhancer network may offer therapeutic strategies for pancreatic cancer.